Corcept reports a 59% response rate and 7.2-month median PFS with Lifyorli, nab-paclitaxel and bevacizumab in Phase 2 BELLA.
Written By: Mayuri Vaja, PharmD
Reviewed By: Pharmacally Editorial Team
Corcept Therapeutics has reported positive results from Part A of its Phase 2 BELLA trial (NCT06906341), evaluating Lifyorli® (relacorilant) combined with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The triplet combination achieved a median investigator-assessed progression-free survival (PFS) of 7.2 months and an objective response rate (ORR) of 59%. Median overall survival (OS) had not been reached at the primary analysis.
The findings provide an early clinical assessment of adding bevacizumab to the relacorilant and nab-paclitaxel treatment backbone. However, BELLA’s single-arm design limits conclusions about the contribution of bevacizumab to the observed outcomes.
BELLA Reports Encouraging PFS and Response Results
BELLA Part A was an open-label, single-arm Phase 2 study involving 95 women with recurrent, platinum-resistant ovarian cancer across approximately 45 sites in North America, Europe and Asia-Pacific.
The triplet regimen achieved a median PFS of 7.2 months, while 59% of patients experienced an objective response. At six months, 88% of patients were alive.
Corcept contextualized these findings using results from the separate Phase 3 ROSELLA trial, which evaluated relacorilant plus nab-paclitaxel against nab-paclitaxel alone. In ROSELLA,median PFS was 5.4 months with the combination and 3.9 months with nab-paclitaxel alone. Corresponding ORRs were 37% and 30%, while six-month OS rates were 82% and 77%, respectively.
Although the BELLA results appear numerically higher, these comparisons do not establish that adding bevacizumab improves efficacy. Differences between the trial populations and study designs may influence outcomes, and BELLA did not include a randomized comparator. Direct evidence of bevacizumab’s incremental contribution is therefore lacking.
Bevacizumab-Naive Patients Showed Higher Response Rates
Approximately half of the BELLA participants had not previously received bevacizumab. In this subgroup, median PFS was 8.1 months, ORR was 66%, and the six-month OS rate was 91%.
These findings identify prior bevacizumab exposure as a potentially relevant factor for further investigation. However, the subgroup results do not establish that bevacizumab-naive patients derive greater benefit from the triplet, nor do they establish a predictive biomarker for treatment selection. Further analyses and comparative evidence are needed to clarify the significance of this observation.
GR Antagonism Provides the Treatment Rationale
Relacorilant is a selective glucocorticoid receptor (GR) antagonist that competitively binds to the receptor and blocks cortisol-mediated effects. GR signalling has been investigated as a contributor to tumour-cell survival and resistance to chemotherapy-induced apoptosis.
Combining relacorilant with nab-paclitaxel and bevacizumab is intended to evaluate whether GR antagonism, alongside chemotherapy and anti-angiogenic treatment, can improve clinical outcomes. BELLA’s reported results provide a clinical signal supporting further investigation, but they do not independently establish the mechanism responsible for the observed responses.
Safety Findings and Regulatory Context
The most common adverse events reported in BELLA Part A, occurring in at least 25% of patients, were neutropenia, anemia, nausea, asthenia, nail disorders, peripheral neuropathy, fatigue and leukopenia. Corcept reported that the safety findings were consistent with the known profiles of the individual agents and with previous experience using relacorilant plus nab-paclitaxel, with no new safety signals identified.
Established risks associated with Lifyorli treatment include neutropenia and severe infections, adrenal insufficiency, embryo-fetal toxicity and interactions with systemic glucocorticoids. These prescribing-information risks should be distinguished from adverse events specifically reported in BELLA.
Lifyorli is FDA-approved in combination with nab-paclitaxel for eligible adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. The addition of bevacizumab to Lifyorli and nab-paclitaxel remains investigational.
Complete BELLA Data Expected in 2027
Corcept plans to present the complete BELLA Part A results at a medical conference in 2027. Further data will help clarify the durability of responses, longer-term survival outcomes and the safety profile of the triplet regimen.
For now, BELLA establishes a preliminary efficacy signal for the three-drug combination, including a notable response rate and encouraging results in bevacizumab-naive patients. Whether adding bevacizumab provides a clinically meaningful benefit beyond relacorilant and nab-paclitaxel remains an open question.
Reference
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer, Corcept Therapeutics, 26 October 2026
Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers, ClinicalTrials.gov ID NCT06906341
About the Writer
Mayuri Vaja (Linkedin) is a Pharm.D professional with a strong interest in clinical research, pharmacovigilance, and medical writing, supported by certifications in pharmacovigilance and academic projects exploring AI in healthcare and drug safety.
With a growing focus on evidence-based healthcare and scientific communication, she is developing expertise in clinical research and translating healthcare evidence into clear, meaningful content.
As a Pharmacally healthcare writer, Mayuri is committed to creating accurate, research-driven, and clinically relevant healthcare content while continuously strengthening her professional skills.